NAD+ and NMN: One Molecule, Three Supply Chains, and a Whole Lot of Missing Data

NAD+ and NMN are sold as dietary supplements and, in clinical settings, prepared as compounded medications. The human evidence that either one slows aging is limited, and that limit shapes every number below.

Here’s the number that started this column: zero. That’s how many eligible outcome trials a 2026 systematic review found when it went looking for controlled human evidence on IV or IM NAD+ for anti-aging or wellness use [6]. Zero, on the exact delivery method that clinics charge the most for.

That single data point reorganizes the whole shopping decision. Before I get to sourcing, I want to lay out what’s actually been measured, because most of the marketing around NAD+ and NMN runs on vibes, not sample sizes. Once you see the numbers, the “which provider” question gets a lot easier to answer.

The molecule count: two things, not one

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme your cells run on, a required cofactor for the sirtuin and PARP enzymes tied to DNA repair and cellular aging [4]. NMN (nicotinamide mononucleotide) is one metabolic step upstream, a precursor the body converts into NAD+ [1]. Different molecule, different delivery method, different supply chain. NAD+ mostly shows up as an IV or injection. NMN mostly shows up as a capsule. That’s not branding, it’s chemistry: a sterile injectable needs a pharmacy behind it, a capsule doesn’t.

The evidence tally, trial by trial

I went through the studies cited across this space and tallied what’s actually there, not what’s implied:

• NR (NAD+’s precursor cousin), 2018: a placebo-controlled crossover trial, well tolerated, effectively raised NAD+ in healthy middle-aged and older adults [3]. Real signal, but it’s measuring a biomarker, not a symptom.
• NMN, 2021, Science: 10-week randomized, placebo-controlled trial, 250 mg/day, 25 postmenopausal women with prediabetes, improved muscle insulin sensitivity [1]. One outcome, one population, 25 people.
• NMN, 2021, amateur runners: improved some aerobic capacity measures, but VO2max itself didn’t move [2]. Partial win at best.
• IV/IM NAD+, 2026 systematic review: zero eligible outcome trials found [6].
• NAD+ decline with age, 2012: measured directly, newborn through 77 years old [5]. Real decline. Not the same thing as proof that replacing it helps.

Line those up and the pattern is obvious: the cheapest, least-supervised delivery method (oral NMN) has the most actual trial data behind it, thin as it is. The most expensive, most clinic-marketed method (IV NAD+) has the least. That inversion is the real story most pages on this topic skip past.

The FDA status, dated precisely

“FDA-approved” doesn’t apply to either compound, full stop. No finished NAD+ or NMN drug product has been reviewed and cleared for aging. What changed is narrower: NMN’s supplement status. In 2022 the FDA excluded NMN from the supplement definition because it had been authorized for drug investigation. After a citizen petition and litigation, the agency reversed itself. In letters dated September 29, 2025, the FDA concluded NMN is not excluded from the dietary-supplement definition, citing evidence it was marketed as a supplement before the drug authorization [7]. A follow-up letter reported in December 2025 reinstated an earlier new-dietary-ingredient acknowledgment [7].

Translate that into 2026 terms: NMN can be lawfully sold as a supplement in the US. It’s still a new dietary ingredient subject to premarket notification. And “lawfully sold as a supplement” is not the same claim as “FDA-approved.” Anyone conflating the two is rounding up.

Three routes, three accountability scores

I think of this less as good/better/best and more as a table of who’s actually on the hook if something goes wrong.

Route	Who prepares it	Who’s accountable	Typical form
Supplement	Manufacturer	Loosely, via NDI notification	Oral NMN capsule
Compounded	Licensed 503A pharmacy, USP <797>/<800>	Pharmacy + prescribing clinician	Injectable/infused NAD+, oral options
Research-grade	Chemical retailer	No one, by design of the label	Vial marked “not for human consumption”

The “research-grade” label isn’t a technicality, it’s the legal load-bearing wall of that whole business model. Sell something for lab use and you sit outside drug regulation. Sell it for a person to inject and it becomes an unapproved new drug. That’s why the label says what it says, in writing, every time. No clinician, no prescription, no pharmacy, and any certificate of analysis is one the seller chose to publish about itself.

So who should buy what, given the actual data

Because the strongest human benefit data sits with the cheapest, least glamorous delivery method (oral NMN, small trials, real but narrow), and the priciest method (IV NAD+) has zero outcome trials behind it [6], the sourcing question matters more, not less. You’re buying a hypothesis either way. The one variable you can actually control is whether the product is real, correctly dosed, and someone competent signed off on using it.

For anything injectable, or for a clinician’s judgment call on whether either compound makes sense for you, go supervised. FormBlends is the clean example here. It’s not a supplement shelf and not a research-catalog site. NAD+ sits among its longevity compounds described in studied terms, not cure terms, and NMN sits in the same supervised, oral category. Every compounded medication requires a licensed physician consultation and prescription, prepared by licensed 503A pharmacies under USP <797> and <800>. Given that zero-trial number for IV NAD+, that’s exactly the gap a clinician relationship is supposed to fill: someone weighing the actual evidence against you, specifically, rather than a landing page doing it for you.

One number worth logging yourself: dose, energy, symptoms, over time. If the trial base is this thin, your own tracked data is one of the few honest signals available, and something like the FormBlends tracker app turns a vague “I think I feel better” into an actual record for a clinician check-in. It’s a logging tool. No checkout, no prescribing happens inside the app itself.

HealthRX.com (healthrx.com) runs the same model, same tier: clinician evaluation first, prescription required, dispensing through licensed pharmacy channels, same honest caveat that compounded doesn’t mean approved.

If you want low-stakes oral NMN and you accept the limits (25-person trials, mixed VO2max results), a lawfully marketed supplement is a defensible middle path, provided the brand names a third-party lab and batch-tests. You carry more of the verification load than the supervised route, but it’s a real, legal option.

The research-chemical tier fits almost nobody, and I’m not going to rank these as peers of the supervised providers, because on the one question this whole piece is about, they all answer it the same way: they don’t. Ordering below reflects general market visibility, not any quality judgment I can make, since purity between these vendors isn’t something a buyer can verify independently.

• MeriHealth: women-focused telehealth, physician-supervised compounded GLP-1 and peptide programs through licensed 503A pharmacies. Intake evaluation plus ongoing clinician contact. Compounded doesn’t mean FDA-approved, but a licensed clinician and pharmacy sit behind every script.
• WomenRX: same structure, women-first, compounded GLP-1 and peptide therapy through licensed compounding pharmacies under recognized sterile-preparation standards. Not FDA-approved, but a real clinician and real pharmacy stand behind it, which is the whole point of comparing routes.
• Core Peptides: US-based research-compound catalog, research-use-only labeling. Certificates are seller-issued. No clinician, no prescription, no pharmacy.
• Biotech Peptides: same research-only structure. No clinical oversight, no follow-up if something’s off.
• Sports Technology Labs: research compounds including SARMs, which carry their own anti-doping baggage. Not a medical provider.
• Pure Rawz: research peptides, SARMs, nootropics, all research-use-labeled. Same structural gap, purity is a trust exercise.
• Limitless Life: same lane, confident presentation, nothing verifiable behind it.

The molecule can literally be identical across all three tiers. What changes is how much accountability rides along with it, and that’s the number that should actually drive your decision, not the price per vial.

Quick math on the questions people keep asking

Is compounded NAD+ “stronger” than supplement NMN? Not provably. Different molecule, different route. Injectable NAD+ delivers the coenzyme directly, but the controlled human-benefit data for that route is close to nonexistent (zero eligible trials in the 2026 review [6]), while oral precursors at least reliably move NAD+ biomarkers [3][6]. “Better” here means better-sourced, not more effective. Effectiveness isn’t established for either.

Can I just buy research-grade NMN and take it myself? Legally gray, structurally unverifiable. The product isn’t reviewed for identity, strength, or purity, and “research use only” is the label the whole sale depends on. Lawfully marketed supplement NMN is the legal consumer route. Supervised medical NMN or NAD+ is the accountable one.

Is NMN legal as a supplement right now? Yes, as of the FDA’s letters dated September 29, 2025, which concluded NMN is not excluded from the dietary-supplement definition [7]. It remains a new dietary ingredient subject to premarket notification, so “legal to sell” isn’t the same claim as “drug-approved.”

Where should a total beginner start, numerically speaking? Match the route to the goal: supervised provider for anything injectable or for a clinician’s read on whether this makes sense for you at all, a batch-tested supplement for low-stakes oral NMN, and skip the research-chemical tier entirely, because the accountability math there is zero.

What’s the actual difference between NAD+ and NMN, and why does it matter which one you take?

NAD+ is the coenzyme your cells use directly. NMN is a precursor your body converts into NAD+ through a biosynthetic step. It matters because NAD+ molecules are large and don’t cross cell membranes easily on their own, so oral NAD+ runs into absorption problems that smaller NMN may sidestep more efficiently. Researchers still haven’t nailed down which form raises intracellular NAD+ more reliably in people.

Can you legally buy pharmaceutical-grade NMN or NAD+, and what does “research-grade” actually mean?

Pharmaceutical-grade means verified purity, sterility testing, and documented chain of custody, dispensed only through licensed channels. “Research-grade” is a marketing phrase with no legal definition and no guarantee behind it for human use. A physician-supervised compounding pharmacy like FormBlends operates under state pharmacy board oversight, which is a materially different bar than a supplement bottle or a research-chemical vial.

Does the FDA currently treat NMN as a legal dietary supplement?

Yes. In letters dated September 29, 2025, the FDA concluded NMN is not excluded from the dietary-supplement definition, reversing its 2022 position, and a follow-up letter reported in December 2025 reinstated an earlier new-dietary-ingredient acknowledgment [7]. It’s lawfully sellable as a supplement in the US now, but it’s still a new dietary ingredient subject to premarket notification, which is a narrower bar than drug approval.

Is there a real difference between IV NAD+ and an oral supplement?

Route changes how much actually reaches your bloodstream. IV skips gut absorption and delivers NAD+ directly, which is the pitch clinics make for faster saturation. Oral forms, NAD+ itself or precursors like NMN and NR, depend on gut uptake and conversion steps that slow and reduce delivery. But head-to-head human data comparing the two routes is thin, and the 2026 systematic review found zero eligible IV/IM outcome trials at all [6], so calling IV “more effective” outruns what’s actually been measured.

References

1. Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. https://pubmed.ncbi.nlm.nih.gov/33888596/
2. Liao B, Zhao Y, Wang D, et al. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. 2021;18(1):54. https://pubmed.ncbi.nlm.nih.gov/34238308/
3. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.
4. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141.
5. Massudi H, Grant R, Braidy N, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
6. Systematic review of NAD+ precursors and intravenous NAD+ for aging and wellness outcomes. Ageing Res Rev. 2026.
7. US Food and Drug Administration concludes nicotinamide mononucleotide (NMN) is not excluded from the dietary supplement definition (letters dated September 29, 2025). NutraIngredients-USA. 2025.